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[A1]
Clinical phenotype of individuals with germline mutations 
in the PMS2 gene
Leigha Senter, Mark Clendenning, Heather Hampel, 
Kaisa Sotamaa, Albert de la Chapelle
Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University,
2050 Kenny Road, Columbus, OH 43221
Key words: PMS2, Lynch syndrome, HNPCC
Background: Individuals with Lynch syndrome (also
known as hereditary nonpolyposis colorectal cancer
syndrome; HNPCC) have an increased risk of
developing multiple types of cancer, especially colon
and endometrial. Germline mutations in one of four
mismatch repair (MMR) genes (MLH1, MSH2, MSH6,
or PMS2) cause Lynch syndrome, which accounts for 
2-5% of all colon cancers. Fewer Lynch syndrome
associated mutations in PMS2 have been described
in comparison to the other MMR genes. This is due
at least in part to the difficulty in interpretation of
results of PMS2 mutation analysis given a large family
of pseudogenes located on the same chromosome.
However, using long range PCR and multiplex ligation
probe-dependent amplification (MLPA), germline
mutations in PMS2 have been accurately identified.
The identification of these mutations has created 
a cohort of PMS2 mutation carriers which allows us
to describe the clinical phenotype of PMS2-associated
Lynch syndrome.
Methods: 28 individuals (26 probands with colon
cancer and 2 probands with endometrial cancer) whose
immunohistochemistry (IHC) results showed absence of
PMS2 protein and presence of MLH1, MSH2, and
MSH6 proteins were tested for germline mutations in
the PMS2 gene using long range PCR, sequencing, and
MLPA. Tumors from 23 of these participants showed
microsatellite instability (MSI) while MSI results were
unavailable for the remaining 5 individuals. Complete
clinical data and family history data were available for
all participants.
Results: Of the 28 individuals in this series, 
20 (71.4%) were found to have deleterious or putatively
deleterious germline mutations in the PMS2 gene. Two
of these individuals were found to be compound
heterozygotes for germline PMS2 mutations. Of the 
20 individuals with mutations, 13 met Bethesda criteria
(65.0%), 2 met Amsterdam I criteria (10.0%), and 
5 did not meet any published family history criteria for
HNPCC (25.0%). Four of the 20 mutation carriers
had a parent with an HNPCC-associated tumor.
Samples from at least one parent or other informative
relative were available for testing in 5 of the mutation
carriers and mutations were identified in one
parent/relative in each of these cases. Ages of cancer
diagnosis in mutation carriers range from age 
14 to 82 with a mean of 48.0 years.
Conclusions: Clinical characteristics of PMS2
germline heterozygotes have been rarely described to
date given the difficulty in identifying these mutations.
Based on the current results it is suggested that families
that have PMS2 mutations do not often fit Amsterdam
criteria for HNPCC. There are several possibilities for
this observation. It is possible that PMS2 has signifi-
cantly reduced penetrance. This has been previously
suggested in case reports of PMS2 compound
heterozygotes and homozygotes and is supported by
evidence in this series of probands in which only 4 of
the 20 mutation carriers (20%) had an affected parent
with an HNPCC-associated malignancy. Some
researchers have suggested that PMS2 could have 
a higher de novo mutation rate than the other MMR
genes. At least one parental sample was tested for 
5 of 20 mutation carriers and a parent was found to
have the PMS2 mutation in each case, providing no
evidence of de novo mutation. None of these 
5 mutation carriers had an HNPCC-associated
malignancy. This too adds circumstantial evidence to
the potentially reduced penetrance in PMS2. As we
gain more data from PMS2 mutation carriers and
further evaluate the penetrance of PMS2 mutations, 
Abstracts from the 10th Annual Meeting of the Collaborative Group 
of the Americas on Inherited Colorectal Cancer, 
November 9-10, 2006, Nashville, Tennessee, United States
Clinical Science Podium Presentations
Hereditary Cancer in Clinical Practice 2007; 5(1) pp. 31-50
Hereditary Cancer in Clinical Practice 2007; 5(1)32
Abstracts
it may become necessary to reconsider the surveillance
and screening recommendations for families with
PMS2 mutations.
Funding: NCI R01 #CA67941.
[A2]
Current Practices and Opinions of Cancer Genetics Professionals
Regarding MYH Genetic Testing
Kimberly Banks1,2, Katrina Lowstuter2, Kathleen Blazer2, 
Jeffrey Weitzel2
1St. Joseph Hospital Cancer Genetics Program, 1100 W. Stewart Drive, Orange, CA 92868;
2City of Hope National Medical Center, Clinical Cancer Genetics Department, 1500 Duarte
Road, Duarte, CA 91010
Key words: MYH, genetic testing, current practices
Background: There is controversy among cancer
genetics professionals regarding when new genetic tests
for hereditary cancer syndromes should be offered
clinically and what constitutes a clinically relevant
genetic test. Genetic testing for MYH is commercially
available, but the clinical utility of this test and the
parameters of its application remain unclear. To help
reach a cogent practice consensus we surveyed cancer
genetics healthcare professionals from November 2005
to January 2006 about their MYH genetic testing
practices, the rationale for these practices, and opinions
regarding clinical utility.
Methods: Members of the National Society of
Genetic Counselor Familial Cancer Counseling Special
Interest Group, the Oncology Nursing Society Genetics
Special Interest Group, the International Society of
Nurses in Genetics, the National Cancer Institute’s
Cancer Genetics Services Directory, the Collaborative
Group of the Americas on Inherited Colorectal Cancer,
and Southern California, Colorado, Ohio, and
Oregon/Washington Kaiser Permanente Genetics
Departments were contacted three times by email with
the invitation to participate and link to the online survey.
Statistical analyses (not all reported) included ANOVA,
Tukey HSD for multiple comparisons, Cronbach’s alpha,
Pearson Correlation, and Pearson Chi-Square test.
Results: Of 336 responses, 58% were genetic
counselors, 25% were nurses, and 10% were physicians.
Among the 77% who had seen a patient(s) for polyposis
evaluation, 69% had ordered MYH testing. The two
primary reasons for ordering MYH genetic testing were
to provide information for family members (96%) and
that the patient’s screening and risk behavior may be
modified by the knowledge (93%). The primary reasons
for not ordering MYH analysis were unclear healthcare
recommendations for monoallelic (72%) and biallelic
(64%) MYH carriers (72%), and that the patient was not
interested (68%). For a patient with 5 colorectal
adenomas at age 40 with a negative APC analysis and
no significant family history, 21% would order MYH
analysis, 30% would not, and 49% were uncertain. 
For the same scenario but with 20 or 100 adenomas,
73-78% would order MYH testing, 2% would not, and
21-25% were uncertain. For a patient with colorectal
cancer at age 40, HNPCC ruled out, and no polyposis
or significant family history, 19% would order MYH, 35%
would not, and 46% were uncertain. When asked if 
a new mechanism should be developed to provide
guidance for when newly available cancer genetic tests
should be used clinically, 70% responded in favor.
Conclusions: Our findings indicate that MYH
ordering practices and rationale are fairly consistent
with the published literature but that providers are
uncertain of the specific parameters within which to
utilize this test. Additionally, the majority of participants
expressed interest in test specific guidelines. Given the
paucity of such guidelines for MYH genetic testing, the
CGA-ICC may wish to consider publishing a consortium
policy statement.
Funding: This research was funded in part by the
National Society of Genetic Counselors Familial
Cancer Special Interest Group Grant Award. 
[A3]
Evaluating Lynch Syndrome in Very Early Onset Colorectal Cancer
Probands without Apparent Polyposis
Kory Jasperson1, Katrina Lowstuter2, Thuy Vu3, 
Angela Schwab1, Lisa Bredthauer1, Deb Neklason1, 
Miguel Rodriguez-Bigas3, Randall Burt1, Jeffrey Weitzel2
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 2City of Hope National
Medical Center, Duarte, CA; 3University of Texas MD Anderson Cancer Center, Houston, TX
Key words: Lynch syndrome, early onset colorectal
cancer, diagnostic strategies 
Background: Early age of colorectal cancer (CRC)
onset is a hallmark of Lynch syndrome and is commonly
used as a selection tool when identifying individuals
suspicious for germline mismatch repair (MMR)
mutations. Previous studies have suggested that
probands with CRC diagnosed at less than age 36
have a high likelihood of carrying an MMR mutation
regardless of family history. Debate exists as to whether
evaluation of Lynch syndrome in these individuals with
early onset CRC should begin with germline genetic
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testing verses tumor analysis (microsatellite and/or
immunohistochemistry analysis for MMR genes). Here
we assess probands with early onset CRC for Lynch
syndrome and discuss the potential expanded
differential diagnoses of MYH-associated polyposis
(MAP), attenuated familial adenomatous polyposis
(AFAP) and Li-Fraumeni syndrome.
Methods: We evaluated 96 probands with CRC
diagnosed prior to age 36 without apparent polyposis
using populations from two high-risk cancer clinics and
one cancer genetics registry. Probands were categorized
based on clinical criteria met (revised Bethesda
guidelines I, II, III, IV and V, and Amsterdam criteria I
and II) in addition to tumor analysis and MMR germline
genetic testing results. Mutation frequencies were
calculated for each set of clinical criteria and diagnostic
strategies (germline testing verses a staged approach
beginning with tumor analysis) were compared.
Results: Out of 89 probands with family history data
available, 48 (53.9%) met only revised Bethesda
guideline I (CRC diagnosed prior to age 50 years) with
or without revised Bethesda guideline III and thus were
considered “single case indicators”. For 38 of these
single cases, evaluation for Lynch syndrome started with
tumor analysis while7started with germline genetic
testing of the MMR genes (2 probands did not undergo
testing and one participant was excluded due to lack
of genetic testing after an abnormal tumor analysis).
Three of 45 (6.7%) single case indicators were identified
to carry a deleterious or suspected deleterious MMR
mutation compared with 10 of 20 (50.0 %) in the cases
meeting only revised Bethesda guidelines II, IV, and/or
V, and 11 of 14 (78.6 %) in the cases meeting
Amsterdam criteria. After evaluation for Lynch syndrome
revealed no MMR mutations, three families were
identified to have additional clinical features suspicious
for alternate genetic diagnoses and were documented
to have a germline MYH, APC or TP53 mutation.
Conclusions: It appears from our data that single
cases of very early onset CRC infrequently have
identifiable germline MMR mutations. Furthermore our
findings suggest that testing strategies in these probands
should begin with a staged analysis of MSI and/or IHC
followed by germline genetic testing when indicated.
Careful attention to evolving or additional clinical
features (e.g. polyps and other cancers) is warranted
in these cases and may lead to an alternate genetic
diagnosis in CRC cases diagnosed prior to age 36.
Future studies are needed to better define the frequency
of MYH, APC and p53 germline mutations in these
early onset CRC probands.
[A4]
Population-based analysis of cancers in large Utah families 
with known mismatch repair gene mutations 
Jonathan Warner, Deborah Neklason, Angela Schwab,
Jared Cox, Scott Kuwada, Christopher Dechet, 
Randall Burt
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Key words: HNPCC, cancer risk, population-based
Background: Hereditary non-polyposis colorectal
cancer (HNPCC) is caused by mutations in DNA
mismatch repair (MMR) genes and is hallmarked 
by incomplete penetrance of early onset colon and uterine
cancers. Pancreatic, small intestine, stomach, urinary 
tract, and ovarian cancers are also associated with 
this syndrome. Interestingly, the cancers appear to
demonstrate geographic variations in penetrance possibly
due to differences in genetic pools or environmental
factors. Current estimates of cancer risks for HNPCC have
been developed mainly from families seeking medical
advice. This can lead to biased estimates due to self
ascertainment, small family size, lack of communication
within families, and the inability to obtain medical
documentation spanning several generations. The goal
of this study is to examine the prevalence of all cancers
in HNPCC families using large Utah pedigrees with
confirmed MMR mutations as compared to the Utah
population. Probands were ascertained through the
Familial Colon Cancer Registry. The Utah Population
Database (UPDB) includes 1.6 million genealogy records
linked to 136,000 cancer cases from the Utah and Idaho
Cancer Registries dating back to 1967, as well as Utah
birth and death certificates.
Methods: MMR mutation positive probands
representing 13 kindreds linked to UPDB genealogies
were identified. The most informative founder of the
HNPCC kindreds, going back as far as 5 generations,
was selected by evaluating the increased prevelance
of colon and uterine cancers diagnosed between 
16 and 60 years in the kindred as compared to the
Utah population. The minimal p-value combined with
pedigree evaluation for linear transmission was used
in selection of the founder. Once the founders were
identified, the observed versus expected number of
cancers in all individuals descending from the founding
couple were extracted from UPDB.
Results: The 13 HNPCC families had mutations in
MLH1, MSH2, and PMS2; the exact mutations are
being verified through medical records. Pedigrees
ranged from 2 to 6 generations with an average of
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123 members (range 5-592). Cancers in 2-fold excess
are listed in the adjacent table.
Conclusion: Population-based data from UPDB give
an unbiased perspective of cancer risks in large HNPCC
families. Colorectal, uterine, small intestine, pancreatic,
and urinary tract cancers were found in statistically
significant excess. Interestingly, ovarian cancer is not in
excess. One striking observation was that 2 of the 
3 mouth cancers were of the parotid gland.
[A5]
Transitions to Adulthood in Individuals with FAP
T Rich, W Kohlmann, E Petty, S Gruber
The University of Michigan, Ann Arbor, MI
Familial adenomatous polyposis (FAP) is a paradigm
for predictive genetic testing in childhood. This
exploratory study aims to identify and describe the
psychosocial, reproductive, and medical decision-making
issues that arise as children with FAP enter adulthood.
Young adults represent an important age group in which
to study the impact of genetic knowledge since the
responsibility of health care management is undertaken
for the first time and important decisions with life-long
ramifications are made. 
Methods: Validated quantitative questionnaires and
semi-structured qualitative interviews were used to
explore young adults’ (age 19-28) perceived disease
burden, FAP-specific knowledge, self-concept, social
support, and decision-making regarding education,
career, living situations, relationships, reproduction,
and medical care. Interviews were coded using a novel
theoretical framework that combined models of self-
-concept and risk-resiliency theory.
Results: A total of ten young adults and eight parents
participated in the study. The majority of participants
reported positive opinions of themselves; however, there
were concerns in three major domains: independence,
peer approval, and reproduction. Financial strains, living
situations, and poor health contributed to loss of
independence. Peer approval concerns were related to
perceived undesirability to the opposite sex, negative
body image, fear of rejection, and appearing less
competent. Reproductive concerns included fearing
feeling guilty, not wanting to put a child through what
they went through, and not feeling healthy enough to
carry a pregnancy. We noted that those with positive
outlooks toward FAP tended to be adaptive, goal-
-oriented, had a strong sense of self, strong social
support, and were not influenced by what other people
thought of them. 30% of participants did not seem to be
receiving appropriate medical care for reasons including
financial/insurance strain and lack of medical savvy and
self-advocacy. The findings from this descriptive study
demonstrate a need for better preparation and support
as individuals with FAP transition to adulthood.
[A6]
The Intricacies of Making a HIPAA Compliant Authorization Form
for a Research Registry
Lisa Bredthauer1, Angela Schwab1, Stephanie Argoitia2,
Randall Burt1
1Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah
84112; 2University of Utah Health Care, HIPAA Privacy Team, 50 North Medical Drive,
Salt Lake City, Utah 84132
Key words: HIPAA authorization, medical record
release, and privacy
Background: In short, the Health Insurance
Portability and Accountability Act (HIPAA) and its Privacy
Rule controls the way a health organization or covered
entity safeguards an individual’s (living or deceased)
protected health information (PHI). HIPAA legislation
was passed in 1996 and the compliance date for the
Privacy Rule component of HIPAA was April 14, 2003. 
Although researchers and clinicians are bound by
these regulations, these rules are commonly misun-
Table 1. (A4)
Cancer Observed Expected Ratio Obs/Exp
Mouth 3 0.861 3.48
Thyroid 2 0.889 2.25
Small intestine 2 0.273 7.33
Colorectal 34 4.271 7.96
Anal 1 0.142 7.05
Bone 1 0.242 4.13
Uterine 10 1.385 7.22
Kidney 4 0.860 4.65
Ureter 1 0.052 19.12
Bladder 5 1.740 2.87
Renal Pelvis 2 0.084 23.84
Other 13 5.888 2.21
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derstood, misinterpreted, and consequently misre-
presented to patients and research participants. Some
health care providers may falsely assume that their
current documents, including medical record release
forms, are HIPAA compliant, especially when they are
Institutional Review Board (IRB) approved. A question
about the HIPAA compliance of a medical record release
form that was IRB approved prompted the Familial
Colon Cancer Registry (FCCR) to re-examine the HIPAA
regulations and modify their authorization documents. 
Methods: To develop an HIPAA compliant medical
record authorization form, the HIPAA documents were
reviewed thoroughly and interpreted by the FCCR staff
and HIPAA compliance officers at the University of
Utah. The HIPAA Privacy Rule was reviewed and the
details of the authorization form and informed consent
were outlined. After considerable discussion, review,
and editing, a release form was approved and is now
in use by the Registry and other studies in the High Risk
Cancer Clinics at Huntsman Cancer Institute. 
Results: From this evaluation, a detailed explanation
of the proper way to obtain authorization and informed
consent and the components needed to produce 
a compliant HIPAA medical record release form were
compiled. An example HIPAA compliant medical
record authorization form has been established.
Registry coordinators across the country will be able
to use this easy to follow summary to bring their
authorization forms into compliance. 
Conclusions: To the lay person, the HIPAA Privacy
Rule is 33 pages of convoluted language written from
a lawyer’s perspective. It is designed to protect patients
and their identifiable and protected health information.
Unfortunately, the language is so difficult to decipher
that even seasoned researchers and clinicians often
do not fully understand the intricacies of the Privacy
Rule. Furthermore, translating the confusing HIPAA
language to patients is often a mind-boggling
experience. To fully understand HIPAA and the
protections it entails to patients, this project involved
detailing the HIPAA regulations and each of their
components into an easy to follow format. A compliant
medical record release form was also produced. It is
the hope that this example document can be used by
registries across the country. Of note, individual
research centers may have slightly varying regulations.
Local HIPAA compliance officers can be a beneficial
addition to the team when addressing these issues.
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Small pool PCR analysis of MSI in familial colorectal cancer 
type X identifies an attenuated MSI phenotype suggesting
hypomorphic mutation in mismatch repair genes as the basis
Mary Coolbaugh-Murphy1, Jing-Ping Xu1, Crystal Simien1, 
Louis Ramagli1, Barry Brown1, Noralane Lindor2, 
Stephen Gallinger3, Robert Haile4, Daniela Seminara5, 
Marsha Frazier1, Michael J Siciliano1
1The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; 2Mayo Clinic,
Rochester, MI 55905; 3Mt. Sinai Hospital, Toronto, Ontario, CA M5G 1X5; 4USC/Norris
Cancer Ctr., Los Angeles, CA 90033; 5NCI, Bethesda, MD 20892
Key words: MSI, small pool PCR, familial colorectal
cancer type X
Background: Nearly half of families meeting
Amsterdam-1 (AC-1) criteria for hereditary nonpo-
lyposis colorectal cancer (HNPCC) do not show
microsatellite instability (MSI) by traditional assays, nor
have mutations or expression defects in mismatch repair
(MMR) genes been identified in them. They have been
designated “familial colorectal cancer type X” (FCCX)
(JAMA 2005; 293: 1979). We have recently developed
a sensitive and quantitative assay for MSI, small pool
PCR (SPPCR), which has been shown to be sensitive
enough to quantify low but significant levels of MSI in
the PBLs of normal individuals (Mech Aging Dev 2005;
126: 1051). There has been little comprehensive
analysis of MSI by SPPCR in the various categories of
non-polyposis colon cancer. 
Purpose: Determine if MSI exists in FCCX tumors
and suggest a genetic basis for it.
Materials and methods: Using SPPCR, we analyzed
paired blood and tumor DNA from 10 unrelated FCCX
patients, alongside age and gender-matched normal
control PBL DNA, and compared the data with those
from paired blood and tumor DNAs of 7 HNPCC 
MSI-H patients having different MMR germline
mutations and the PBLs of 8 sporadic CRC patients.
The D2S123, D5S356, and D17S518 loci were
amplified using hemi-nested PCR, looking at >112
replicates of ~0.75 genome equivalents per locus per
tissue. Mutant fragment (non-progenitor) frequencies
(MF) and 95% confidence intervals (CI) were calculated
using the statistical programs of SPPCR and DSTATTAB,
developed at MDACC. 
Results: While the study on the FCCX matched tumor
and PBLs is ongoing, of the first 10 patients for which we
now have at least 300 fragments analyzed over all 3 loci,
the MF range was 0.05-0.18 for the tumor samples
(mean 0.086, ±0.029 CI) whereas for the patients’
matched PBLs it was 0.01-0.03 (mean 0.016, ±0.011
CI) and for the age-matched normal control PBLs it was
0.015, ±0.004 CI. The PBL data were no different from
our 24 historical controls from normal individuals. 
The MF level of MSI in FCCX tumors was lower than, 
and below the limits of detection by standard PCR of, 
that seen in MSI-H tumors (0.236, ±0.133 CI) for these
same loci. The MSI level in PBLs of MSI-H HNPCC
patients (MF 0.107, ±0.052 CI) was significantly higher
than seen in the PBLs of FCCX patients (above). Finally,
MFs in the PBLs of the FCCX patients were no different
than those seen in the PBLs of the 8 sporadic CRC
patients (0.011, ±0.009 CI).
Conclusions: SPPCR reveals significant levels of MSI
in FCCX tumors, yet they are lower than seen in
HNPCC-MSI-H tumors. Also, MSI-H individuals show
significant MSI in their PBLs while the FCCX patients
do not. These results suggest that FCCX might be due
to MMR missense or hypomorphic mutations having
less severe consequences than those seen in the 
MSI-H patients. Alternatively, mutation in a gene in the
MMR pathway less proximal to the repair event might
evoke this attenuated MSI phenotype. Other possibilities
will be discussed. Screening of FCCX patients for such
mutations might now be valuable for identifying genetic
markers increasing cancer risk.
[A8]
Gonadal Mosaicism in a Family with Familial Adenomatous
Polyposis
Angela Schwab, Therese Tuohy, Michelle Condie,  
Deb Neklason, Randall Burt
Huntsman Cancer Institute at University of Utah, Salt Lake City, UT 
Key words: mosaicism, familial adenomatous
polyposis (FAP), haplotyping
Background: Individuals who are mosaic for genetic
mutations are rare, although they have been reported
in a number of genetic conditions including Duchenne
Abstracts
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muscular dystrophy and Turner syndrome. Mosaicism
is the result of a mutation that occurs early in
embryonic development. The mutated cell goes on to
produce tissues in the body that have the mutation; the
rest of the stem cells do not have the mutation and
develop into unaffected cell lines, causing an individual
to be a mixture of cell types. Gonadal mosaicism
causes an individual’s egg or sperm to be a mixture
of cells with and without the mutation. This case
demonstrates the unique situation of gonadal
mosaicism for a solitary de novo mutation in APC.
Methods: In our clinic, we identified a nuclear family
with two adult children affected with familial adenomatous
polyposis (FAP), confirmed by DNA sequencing of the
APC gene. Each affected child was heterozygous for the
deleterious mutation c.G4729T (E1577X). Each parent
and three remaining siblings were determined to be
unaffected, both by polyp-free colonoscopy and by
normal sequencing results for the G4729T mutation.
Paternity and maternity of all the children were reported
by the parents. To determine if parental mosaicism caused
the two affected siblings, APC haplotyping was
conducted. Allele-specific oligonucleotide (ASO) PCR is
being used to determine the parent of origin. If necessary,
paternity testing will be conducted.
Results: Haplotyping of DNA, obtained from
peripheral blood samples from the parents and the
children, of 4 polynucleotide markers flanking the APC
locus, demonstrated that all five children had inherited
the same APC allele from their father (designated “A”)
(see Figure 1). Both affected children and one
unaffected child share one of the two maternal alleles
(designated “C”). ASO-PCR is being used to
individually amplify the maternal and paternal alleles
from the affected and unaffected children; DNA
sequence analysis will determine whether the G4729T
mutation arose on the paternal or maternal allele. 
Conclusion: The actual incidence of FAP mosaicism
in the general population is unknown. Even though an
individual may appear to represent a de novo mutation,
where parents and siblings would not be at risk for the
condition, clinicians need to consider the possibility of
gonadal mosaicism. For this reason, it is imperative that
both the parents and siblings of an isolated affected
individual be tested for the specific mutation.
[A9]
Common Familial Colorectal Cancer Linked to Chromosome
7q32.33: A Sibpair Study
Deborah W Neklason, Richard Kerber, David Nilson, 
Geraldine Mineau, Randall Burt, Cancer Genetic Network
Sibpair Collaborative Group
Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, 4122, Salt Lake City,
Utah, 84112-5550, Email: deb.neklason@hci.utah.edu, phone: (801) 587-9882
Collaborative Group of Americas on Inherited Colorectal Cancer, Nashville, TN 2006
Key words: sibpair; linkage; colorectal cancer
Background: Colon cancer is one of the most familial
of all cancers with present investigations suggesting that
20-35% of cases arise on the basis of inherited factors.
Genetically defined inherited conditions, however,
account for less than 5% of colorectal cancers. We
hypothesize that the remaining inherited factors are
moderately penetrant genes that are common in the
population. We use an affected sibling pair approach to
identify genetic regions that are coinherited by siblings
with colorectal cancer at an increased rate from what
would be statistically expected by chance.
Methods: Individuals from families with at least two
siblings diagnosed with colorectal adenocarcinoma or
carcinoma in situ were enrolled, medical records
obtained, and DNA collected. Known syndromes were
excluded by medical record review and HNPCC 
by MSI analysis followed by sequencing when tumor
blocks were available. A genome-wide scan on 
152 samples representing 70 kindreds was completed
using deCODE’s 1000 STR marker set at an average
4 cM density. Fine mapping on a total of 186 DNAs
(163 affected and 23 unaffected) from 83 kindreds
was done using deCODE markers at a 1 cM density.
Linkage analysis was accomplished using MERLIN
analysis package. Analysis was run using allele
frequencies of two populations 1) the study participants
and 2) the Caucasian HAPMAP.
Results: MSI analysis was completed on 87 colon






















Figure 1. Pedigree showing genotypic and phenotypic information
(A8)
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have been sequenced for MLH1 and MSH2; 6 are
negative for mutations; 5 have a disease-causing
mutation and were excluded from linkage analysis. The
racial make-up of the individuals in linkage was 87%
white, 4% black, 1% Native American, and 8% other. No
significant linkage was found near genes causing known
syndromes or chromosome 9q22, a region previously
reported by other groups. Linkage analysis revealed three
significant genetic regions: Chr. 4 (D4S3046) at 159 cM
LOD 1.38 (p=0.003); Chr. 7 (D7S669) at 91 cM LOD
2.52 (p=0.0003); and Chr. 7 (D7S2418) at 122 cM
LOD 1.74 (p=0.002). Fine mapping confirmed the chr.
7q31 region, with the peak at 130 cM with an LOD of
3.00 (p=0.0001).
Conclusions: Investigation of sibling pairs with
colorectal cancer identified statistically significant
linkage to chromosome 7q31. No known familial
cancer genes reside here; thus the identified region
may contain a novel susceptibility gene responsible for
common colorectal cancer. Affected siblings with
increased sharing of this locus have a slightly earlier
age of onset (1.2 years) and a slightly lower rate of
metastasis to the lymph nodes. Other pathologic
features did not show a trend with increased sharing.
[A10]
The prevalence of fundic gland polyps and dysplasia in familial
adenomatous polyposis 
Laura Bianchi, Carol Burke, Ana Bennett, Rocio Lopez 
Department of Gastroenterology and Hepatology, 9500 Euclid Avenue, Cleveland Clinic,
Cleveland, OH
Key words: fundic gland polyps, dysplasia, familial
adenomatous polyposis
Purpose: Upper GI cancer is the leading cause of
mortality in FAP patients after colectomy. Fundic gland
polyps (FGPs) have been considered non-neoplastic;
however, cases of gastric carcinoma have been reported
arising from them. Our study aims to 1) determine the
prevalence of FGPs and FGP dysplasia in FAP and 
2) identify whether any endoscopic or demographic
features are associated with the presence of FGP dysplasia.
Methods: This prospective, IRB-approved study
enrolled consecutive FAP patients who presented to the
Cleveland Clinic for upper endoscopic surveillance.
Demographic information and medical history were
collected. On EGD the presence or absence of FGPs
was noted. FGP size (1-5 mm, 6-10 mm, >10 mm),
FGP number (1-20, 21-30, >30), duodenal polyposis
stage, and H pylori status were determined. Systematic
biopsies of FGPs were obtained. Histologic analysis
was performed by one GI pathologist to assess for the
presence of FGP dysplasia, which was classified as:
negative for dysplasia; indefinite for dysplasia; low-
grade dysplasia; or high-grade dysplasia based upon
a priori definitions and standard clinical practice.
Univariable analyses were performed to determine
associations between dysplasia and: family history of
gastric cancer; tobacco use; use of NSAIDs or acid
suppression therapy; presence of Helicobacter pylori
(HP); number and size of FGPs; and stage of duodenal
polyposis. Multivariable logistic regression analysis was
used to study the associations of demographic and/or
endoscopic factors with presence of dysplasia in FGPs.
Results: 40 subjects were enrolled in the study with
a mean age at time of exam of 42.8 (±12.5) years and
55% were males. 33/40 subjects (82.5%) had FGPs.
Subjects with FGPs were less likely to have H. pylori
infection (3% vs. 42.9%; p=0.013).
18/33 subjects (54.5%) had LGD or were indefinite
for dysplasia (15 LGD/3 indefinite). 
Univariable analyses reveal no significant
association between FGP dysplasia and: family history
of gastric cancer; tobacco use; use of NSAIDs; acid
suppressive therapy; presence of HP; number and size
of FGPs; or stage of duodenal polyposis. In the
Table 1. Pathology of siblings sharing the 7q31 allele (170 sib-relationships) (A9)
All cases 0-shared alleles 1-shared allele 2-shared allele
Number of cases 163 26 106 38
Average age diagnosis 58.3 years 59.2 59.1 57.9
Right-sided cancers 42% 27% 44% 26%
Cancer Grade (G1:G2:G3) 11%:70%:19% 13%:75%:13% 12%:76%:12% 12%:72%:16%
Lymph node involvement (N1+N2) 30% 32% 33% 28%
Hereditary Cancer in Clinical Practice 2007; 5(1) 39
Abstracts
multivariable analysis subjects who did not use acid
suppressive therapy are 6.7 (95% CI: 1.05, 43.01)
times more likely to have dysplasia than those who did.
Additionally, subjects with increasing numbers of FGPs
(OR 3.07; 95% CI 0.98, 9.62) and higher 
Spigelman duodenal polyposis stage (OR 1.91;
95% CI 0.87, 4.19) are more likely to have dysplasia.
Conclusion: FGPs are seen in the majority of patients
with FAP. There is a negative association between FGPs
and H pylori. Dysplasia is seen in more than 50% of
subjects with FGPs. Dysplasia is more likely in subjects
not taking acid suppressive therapy; with increasing
numbers of FGPs; and with higher Spigelman duodenal
polyposis stage. Continued prospective evaluation of this
cohort of patients will allow us to garner more knowledge
about the natural history of FGP dysplasia.
Funding: American College of Gastroenterology
research grant.
[A11]
Microsatellite unstable (MSI) human colorectal cancer (CRC) 
is characterized by increased epidermal growth factor receptor
(EGFR) gene expression which is strongly associated 
with mutations in the poly A tract of the 3’ untranslated 
region (UTR) of the EGFR gene
Joongho Shin1, John Mariadason2, Ziqiang Yuan1,
Prashanth Sreeramoju1, Tara Kent1, Kenneth Fordyce1,
John Kim1, Victor Wang1, Thomas K Weber1
1Departments of Surgery and Molecular Genetics, Albert Einstein College of Medicine,
1300 Morris Park Avenue, Ullmann 707, New York, NY 10461; 2Molecular Oncology
Laboratory, Albert Einstein College of Medicine, New York, NY
Key words: colorectal cancer, microsatellite instability,
EGFR
Introduction: EGFR-targeted molecular therapies have
shown significant but modest effectiveness against human
CRC. We recently reported statistically significant
(p=0.001) increased EGFR expression in MSI vs.
microsatellite stable (MSS) human CRC cell lines.* Our
present study tests the hypothesis that increased EGFR
expression in MSI CRC results from 1. Increased EGFR
gene copy number and/or 2. an EGFR gene coding
sequence alteration and/or 3. a 3’ UTR transcription
regulatory sequence alteration. 
Methods: FISH (fluorescent in-situ hybridization)
analysis was employed to measure EGFR gene copy
number in 11 MSI and 17 MSS cell lines. Automated
cDNA sequence analysis was used to search for EGFR
gene sequence variations from wild type in 8 EGFR
over-expressing MSI cell lines.* Targeted sequence
analysis of the Poly A 3’ UTR sequence was performed
on all 28 lines.
Results: FISH analysis of the 28 human CRC cell lines
including 8 EGFR over-expressing MSI lines found no
evidence of EGFR gene amplification. Similarly, sequence
analysis of EGFR cDNA in the 8 EGFR over-expressing
MSI cell lines demonstrated no sequence alterations from
wild type. However, 7 of 8 EGFR over-expressing MSI
lines and 0/17 MSS lines demonstrated a del A sequence
alteration in the poly A(13) tract of the 3’UTR of the
EGFR gene.
Conclusions: We found no evidence to support the
hypotheses that gene amplification or cDNA sequence
variations were associated with the increased EGFR
expression we reported.* However, 88% (7/8) of MSI CRC
cell lines characterized by EGFR over-expression
demonstrated the del A sequence alteration in the 3’ UTR
of the EGFR gene. These results support the hypothesis
that 3’ EGFR poly A sequence alterations contribute to
EGFR over-expression in MSI CRC. We conclude that
these results offer significant insights into the mechanism
of increased expression of EGFR in MSI CRC. 
Funding: for this project was provided by an
American Cancer Society Research Scholar award to
TKW, a Cancer Research Foundation of America award
to ZY and a Colon Cancer ChallengeR Research
Scholar award to ZY.
* Submitted August 06 for SUS peer review for the 2007
Academic Surgical Congress.
[A12]
Why do colorectal cancer patients have inaccurate perceptions 
of the risk to their first degree relatives: differences between
African Americans and Caucasians
Lauren G Bowling1,2, Kelly E Ormond2, Scott M Weissman3,
Robert Kavitt4, David T Rubin5
1City of Hope, Department of Clinical Cancer Genetics; 1500 East Duarte Rd, Mod 103,
Duarte, CA 91010; 2Northwestern University Feinberg School of Medicine; Dept of Medicine
and Center for Genetic Medicine; 3Evanston Northwestern Healthcare, Center for Medical
Genetics; 4University of Chicago Hospitals, Pritzker School of Medicine; 5University 
of Chicago, Department of Gastroenterology
Key words: colorectal cancer, risk perception,
racial/ethnic differences
Background: Results from previous studies revealed
that less than 50% of patients diagnosed with colorectal
Hereditary Cancer in Clinical Practice 2007; 5(1)40
cancer (CRC) knew that their first degree relatives
(FDRs) were at an increased risk for CRC, and the
majority could not identify the appropriate CRC
screening guidelines for their FDRs. Furthermore,
Caucasian patients were significantly more likely to
have an accurate FDR risk perception compared to
African Americans. This pilot study aims to confirm
previous results and to explore factors which influence
CRC patient perception of cancer risks to their FDRs
and how these factors differ between Caucasian and
African American patients.
Methods: Using the survey instrument from previous
studies, literature review, and validated study measures,
the investigators developed a standardized telephone
survey which was administered to 27 CRC patients from
the University of Chicago Cancer Registry. The survey
focused on six areas: (1) demographic characteristics,
(2) knowledge of FDR cancer risk, screening guidelines
and information source, (3) beliefs and knowledge about
the causes of illness and cancer risk factors, (4) CRC
diagnosis experience and patient-physician relationship,
(5) level of mistrust in health care and medical
professionals, and (6) level of participation in religious
and/or spiritual activities and experiences. 
Results: Eight African American and 19 Caucasian
patients participated in this study (~45% response rate).
Approximately half of patients (14 out of 27) understood
that their FDRs were at an increased risk for CRC
compared to the general population. Although not
statistically significant, Caucasians were more likely than
African Americans to have an accurate FDR risk
perception (63.16% vs. 25%; p=.075). Regardless of
race, individuals who had an accurate FDR risk
perception tended to: be younger (p=.003), be younger
at CRC diagnosis (p=.003), have completed a higher
level of education (p=.011), have an annual income of
50,000 or more (p<.001), identify genetics as a CRC
risk factor, have more trust in healthcare and medical
professionals (p=.022), and have a lower level of
religiosity/spirituality (p=.145). Compared to Caucasians,
African Americans were more likely to: be older, be older
at CRC diagnosis, have an annual income of 50,000 or
less, have less knowledge of CRC risk factors, have less
level of trust in healthcare and medical professionals,
and have a higher level of religiosity/spirituality.
Conclusions: A significant number of CRC patients
do not understand that their FDRs are at increased risk
for CRC, especially African American patients. Future
studies are needed to measure factors that influence
FDR risk perception and how these factors vary among
different racial groups. This study suggests that health
care professionals should be aware that CRC patients
may not understand their familial risks and that both
racial and socioeconomic background should be
considered when providing patient education about
familial CRC risk.
[A13]
Is There Something About a New Mutation That Causes Severe
Disease in FAP? A Comparative Study of Probands Stratified 
by Family History
J Church, M Bonardi1, K Bova1, L LaGuardia1, E Manilich
1Department of Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA
Purpose: Approximately 25% of FAP patients have
no family history of the disease. Little is known about
disease expression and genotype in these patients as
previous studies have been flawed by the inclusion of
multiple screened relatives in the control group. To
avoid this bias only probands were included in our
study. We have investigated the influence of lack of
antecedent family history on the clinical and genetic
characteristics of FAP.
Methods: A retrospective review of 176 consecutive
probands with FAP using the Polyposis Registry at the
Cleveland Clinic was carried out. Adequate pedigree
data for at least three generations were available for
50 new mutation and 73 control patients.
Results: Mean age at diagnosis did not differ
between patients and controls (31 and 33 years,
p=0.48). Patients without family history presented with
twice the incidence of colorectal cancer (32% vs. 16%,
p=0.04) and two and a half times the incidence of
desmoid tumors (40% vs. 17%, p=0.008). CRC
developed at a significantly younger age in new
mutation patients (33 vs. 45, p=0.027). No significant
difference between the two groups was found for the
number of colorectal polyps (<100, 100-1000,
>1000), presence of gastro-duodenal polyps and
other extra colonic manifestations and malignancies.
Overall 4 (8%) patients without family history and 7
(9.6%) patients in the family group had died (p=1.0)
at a mean age of 44 and 53 years (p=0.19) and 6
and 7.5 years of follow-up respectively. 24 patients
were tested for APC germline mutation. Detection rate
was similar between the two groups and no specific
APC variation was over-represented in either group.
Conclusions: Significantly higher rates of CRC,
desmoid tumor and malignant transformation at younger
age indicate a tendency toward a more severe form of
polyposis in FAP patients with no family history. These
findings are unlikely to be due to a delay in diagnosis
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and no phenotype-genotype correlation was observed.
Despite the increased severity, new mutation apparently
does not lead to an increase in mortality in FAP.
[A14]
How aware are colorectal surgeons of hereditary colorectal
cancer, and how much does it impact their practices?
James Church, Olivia Fox, Brittany Furman
Section of Research, Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio
Background: Hereditary colorectal cancer is said
to be rare and its rarity is a reason commonly given for
advising physicians to refer such patients to a genetics
center or a registry. We designed this study to discover
just how often colorectal surgeons see patients with
hereditary colorectal cancer, and to measure their level
of interest in this topic.
Methods: A questionnaire was designed that asked
how interested the surgeon was, the number of patients
and families seen with the different syndromes each
year, and the number of colectomies performed for
these syndromes each year. Results were stratified
according to the presence of a special interest in
hereditary colorectal cancer (HCC). The questionnaire
was sent to the 41 training programs in colorectal
surgery and was distributed at a recent meeting of the
American Society of Colorectal Surgeons.
Results: 81 questionnaires were returned; 25 from
surgeons directly involved in an HCC center or registry
and 56 from surgeons who were not. Results in the
table are stratified according to whether the surgeon
had a special interest in HCC or not.
Conclusions: Colorectal surgeons can expect to see
3 to 8 patients with HCC per year. Many have a special
interest in these syndromes and play an active role in
their care. Others without this interest should refer their
patients to specialized centers for help with counseling,
testing and management.
[A15]
An atypical hereditary non-polyposis colorectal cancer syndrome
(HNPCC) family presentation
Dana Farengo Clark, Christopher Deitch, 
Alexandre Hageboutros, Generosa Grana
The Cancer Institute of New Jersey at Cooper, 900 Centennial Blvd, Voorhees, NJ 08043
Key words: MLH1, carcinosarcoma, gynecologic
Background: It is well established that patients with
HNPCC are at increased risk for colon cancer and it
is often thought of as a colorectal cancer dominated
syndrome. HNPCC has also been associated with an
increased risk for extra-colonic cancers and multiple
primary cancers; therefore identifying individuals with
HNPCC can have a major impact on future screening
and medical management options. 
Methods: We describe a unique HNPCC family and
the role that genetic counseling and testing played in
the management of the patient.
Results: The patient is a 42-year-old white female who
presented to her gynecologist with vaginal spotting and
cramping. A pelvic exam revealed a large mass and the
patient was referred to gynecologic oncology for surgical
evaluation. The patient underwent total abdominal
hysterectomy, bilateral salping-oophorectomy and lymph
node dissection. The pathology revealed a Stage IIA
endometrial carcinosarcoma (EC) with zero of seven
lymph nodes positive and the patient was treated with
chemotherapy. During her treatment, the patient asked
to meet with a genetic counselor to discuss her family
history. The patient’s family history was consistent with
the Amsterdam criteria as her father was diagnosed with
colon cancer at 35 and her aunt was diagnosed with
both colon and uterine cancer. Unfortunately, the family
history was not recognized prior to the patient’s
diagnosis. Full sequencing of MLH1 and MSH2 revealed
a deleterious MLH1 mutation (IVS6-2A>G) and the
implications of the testing for the patient and her at-risk
Table 1. (A14) 
Special No Special 
Interest Interest
N 45 36
Heard of LCPG 28 (62%) 16 (44%)
Heard of ICG-HNPCC 34 (76%) 16 (44%)
Heard of CGA 16 (36%) 12 (33%)
Heard of InSiGHT 8 (18%) 8 (22%)
Member of any Group 3 (7%) 0
FAP Pts/Families per surgeon per year 4.0/2.0 1.2/0.8
HNPCC Pts/Families per surgeon per year 4.1/3.3 2.1/1.7
Colectomy/proctocolectomy per surgeon 4.1 1.6
per year
Orders Genetic Testing 82% 56%
Orders Pre-test counseling 71% 56%
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family members was discussed. Due to the patient’s
mutation status and high risk for colon cancer,
colonoscopy was recommended and performed and
revealed a 6cm cecal mass. The patient underwent 
a total abdominal colectomy with an ileorectal
anastamosis and pathology was consistent with a primary
colon cancer, which was diagnosed less than one year
after her EC. To date, her five siblings and four children
remain asymptomatic and have not had genetic testing
despite the urging of our patient.
Discussion: Our patient appears to be one of the
first reports of a carcinosarcoma in an MLH1 family.
The patient’s father developed laryngeal cancer
(a second primary) at the age of 47, which is not
thought to be associated with HNPCC and brings into
question the spectrum of HNPCC cancers. All of the
mutation-positive individuals in this family have
developed multiple primary cancers (including two
women with both colon and uterine cancer) which
make us question whether certain mutations carry
higher risks for multiple primary cancers than others.
This information would have great impact on the
screening and management of individuals in these
families that may carry these mutations. 
[A16]
Two brothers with Muir-Torre syndrome and biallelic MYH
mutations
Paulien van Galen, Francois Bernier
Department of Medical Genetics, Alberta Children’s Hospital, 2888 Shaganappi Trail
NW, Calgary, AB, Canada, T3B 6A8
Key words: MYH associated polyposis, Sebaceous
gland tumors, Muir-Torre syndrome
Background: Muir-Torre syndrome (MTS) is clinically
defined by the presence of sebaceous tumors and
visceral malignancies, usually colorectal cancer (CRC).
It was suspected to be a variant of hereditary non-
-polyposis colorectal cancer (HNPCC) and the iden-
tification of mutations in the HNPCC-associated
mismatch repair (MMR) genes in some patients with MTS
seemed to confirm this suspicion. As MMR mutations are
not identified in all Muir-Torre patients, genetic
heterogeneity cannot be excluded. Recently, a single
patient with sebaceous adenomas and MYH-associated
polyposis (MAP) was reported, raising the possibility that
a subset of these patients may also have MTS. We
recently evaluated two brothers with a history of colonic
polyposis and CRC who both received extensive treatment
by a dermatologist for facial lesions.
Methods: Both brothers underwent a standard
clinical assessment in the cancer genetics clinic as well
as further dermatological evaluation including biopsies
of the facial lesions. Due to the history of colonic
polyposis and colorectal cancer, Colaris AP testing
through Myriad was initiated to screen for mutations
in both APC and MYH. 
Results: The older sibling had a hemicolectomy for
invasive adenocarcinoma of the cecum and multiple
right-sided tubular adenomas. One year later he was
found to have hundreds of minute adenomatous polyps
in the rectum and has since required an ileal pouch anal
anastomosis. His dermatological assessment confirmed
the presence of numerous facial papules that on
pathological examination were confirmed to be
mainly sebaceous hyperplasia or sebaceous
hyperplasia with hamartomatous features. One lesion
had definitive features of a sebaceous adenoma. His
brother had a hemicolectomy for invasive adeno-
carcinoma of the ascending colon, multiple right-
-sided tubulovillous adenomas and synchronous
adenocarcinoma of the small intestine. Derma-
tological exam revealed ~50 umblicated facial
papules in keeping with sebaceous hyperplasia. 
APC mutation analysis revealed no known pathogenic
mutations; however a variant of unknown significant,
E1317Q, was found. Both brothers are homozygous
for the MYH Y165C mutation, which confirmed 
a diagnosis of MYH-associated polyposis.
Conclusions: We report on two siblings with colon
cancer, multiple colonic adenomatous polyps as well as
sebaceous gland tumors including a sebaceous
adenoma. While MYH involvement has focused on
individuals with clinical phenotypes suggestive of
attenuated familial adenomatous polyposis, the full
clinical spectrum of MAP remains to be defined. The
finding of sebaceous adenoma/hyperplasia in our two
patients provides further evidence of genetic
heterogeneity for Muir-Torre syndrome. Sebaceous gland
tumors may be a useful cutaneous marker to help
identify individuals with either MAP or HNPCC.
[A17]
Cowden Syndrome with PTEN Mutation Presenting as
Ganglioneuromatous Polyposis of the Colon with Colonic
Adenocarcinoma
Laura Greene, Wendy C McKinnon, Deborah Cook,
Marcus W Bosenberg, Marc S Greenblatt
University of Vermont, 111 Colchester Ave, Burlington, VT 05401
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ganglioneuromatosis
Background: Cowden syndrome, first described in
1963, is an autosomal dominant condition characterized
by mucocutaneous hamartomas and increased risk of
some visceral malignancies, most notably of the thyroid
and breast. It is caused by mutations in the PTEN gene. 
Methods/Results: We report a case of Cowden
Syndrome with characteristic dermatologic and unusual
colonic manifestations. The male patient had a colectomy
for diffuse colonic polyposis at age 39. Pathology of the
colon showed polypoid ganglioneuromatosis, and an
incidental invasive mucinous adenocarcinoma was found
in one of the polyps, which was associated with
adenomatous dysplasia. Although the adenocarcinoma
was confined to the head of the polyp, metastatic tumor
was found in 3/17 colonic lymph nodes (AJCC T1N1).
Several mesenteric lipomas were also noted. He received
adjuvant chemotherapy and six years later has no
evidence of recurrent cancer. At age 45, he was referred
to the dermatology clinic for evaluation of multiple skin
lesions including: numerous small papules that were
nearly confluent on the nose and nasolabial folds, several
keratoses on the dorsal aspect of both hands, a distinctive
cobblestone appearance on the tongue and oral mucosa,
and a 1 cm dome-shaped nodule on the abdomen.
Biopsy of one of the facial lesions revealed a trichi-
lemmoma and the abdominal lesion was a storiform
collagenoma. The dermatologic findings meet clinical
criteria for the diagnosis of Cowden Syndrome. Analysis
of the PTEN gene in germline DNA showed a truncating
mutation.
Conclusions: Colonic manifestations are a hallmark
of several hamartomatous syndromes related to Cowden
Syndrome, but it is rare to find colonic polyposis, intestinal
ganglioneuromatosis, and colonic adenocarcinoma in
Cowden Syndrome with PTEN mutation. Their presence
should not exclude this diagnosis.
[A18]
The Phenotype of MYH-Associated Polyposis? 
Experience with 6 families
Lisa LaGuardia, James Church, Kim Bova
Familial Polyposis Registries, Department of Colorectal Surgery, Cleveland Clinic,
Cleveland, Ohio
Background: The full phenotype of MYH-associated
polyposis (MAP) is still not known as the syndrome is
relatively new and the number of affected families
relatively sparse. The syndrome often seems to mimic
attenuated FAP except that the pattern of inheritance is
recessive rather than dominant. We report a preliminary
study of the full tumor spectrum seen in 6 MAP families.
Methods: The families of six probands with MAP
were characterized by extensive pedigree building.
Where available, pathology reports were requested to
document the reliability of the family history. All
probands had biallelic mutations of MYH. 
Results: Excluding relatives under the age of eighteen
and the spouses of at-risk relatives, there were 136 at-
-risk relatives in the 6 families. There were 41 affected
(30%), some with multiple tumors. The tumor spectrum
is shown in the table.
Discussion: The colorectal phenotype of these MAP
families is as expected. 17.6% of relatives had adenomas
although less than half of the relatives had screening
colonoscopy. Colon cancers were found in 16 individuals,
usually with an older age of onset. The spectrum of
extracolonic cancers seen in these 6 families is unusual
in the setting of MAP. There were no cases of gastric or
duodenal cancer, but renal cancer occurred in three
different families. There were four cases of prostate cancer
in one family and two with pancreatic cancer in another. 
Conclusion: The phenotype of MAP is evolving.
Detailed studies on phenotype in much large numbers
of families are needed. Renal cancer was present in half
of these families and must be investigated as a possible
component of phenotype.
Table 1. (A18) 
Adenomas Colon Prostate Renal Uterine Pancreas Breast Bone Brain Lung Leukemia
Pts 24 16 5 3 2 2 1 1 1 1 1
Fams 6 5 2 3 1 1 1 1 1 1 1
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Hispanics’ Knowledge, Attitudes and Screening Behaviors
Regarding Familial Colorectal Cancer
Gabriel A Lazarin1, Scott B Cantor2, Christina M Diaz2,
Patrick M Lynch2, Bobbi McGivern2, Sarah J Noblin3,  
Hope Northrup3, Miguel Rodriguez-Bigas2, 
Susan K Peterson2
1Perinatal and Women’s Center, Glendale, AZ; 2The University of Texas M.D. Anderson
Cancer Center, Houston, TX; 3University of Texas Medical School at Houston, Houston, TX
Key words: colorectal screening behavior, Hispanics,
familial colorectal cancer
Purpose: Relatives of colorectal cancer (CRC) patients
are at increased risk of developing CRC themselves,
compared with the general population. Screening
recommendations for persons at risk for familial CRC
advise earlier initiation of screening, compared with
persons at average risk, generally by colonoscopy. Studies
of CRC screening behavior among persons at familial
risk have found that screening adherence is suboptimal,
and most studies have included study populations that
are primarily White. Although Hispanics comprise the
largest U.S. ethnic minority, there are scant data regarding
Hispanics’ knowledge, attitudes, and beliefs regarding
CRC and CRC screening. Furthermore, little is known
about how family communication regarding CRC risk
influences adoption of and adherence to CRC screening
recommendations among increased-risk persons. This
study examined CRC knowledge, CRC screening
behavior, and communication with family and physicians
regarding CRC in a sample of Hispanic CRC probands
and their FDRs. 
Methods: We recruited persons who self-identified
as Hispanic and who were diagnosed with CRC at age
≤60 years, as well as their FDRs age 40 years or older.
Data were collected through in-depth, semi-structured
telephone-administered interviews.
Results: We enrolled n=31 participants (20 CRC
probands, 11 FDRs). Most participants perceived few
barriers to discussing CRC or CRC screening with
members of their immediate family, and CRC probands
often initiated these discussions. Most FDRs had
undergone at least one colonoscopy, many in response
to their relative’s diagnosis. Despite having personal
experiences with CRC, probands demonstrated
knowledge deficits regarding screening and prevention
guidelines for their FDRs. FDRs also lacked knowledge
regarding important CRC risk factors (including polyps)
and screening guidelines for individuals with a family
history of CRC. FDRs perceived few barriers to discussing
family history of CRC or CRC screening with their
physicians. However, FDRs generally did not initiate
discussions with providers about familial CRC risk and
indicated that they would rely primarily on a physician’s
prompting to undergo screening.
Conclusions: A CRC diagnosis in a close relative may
motivate discussion and initiation of screening in Hispanic
families. These results are encouraging; however, gaps
in knowledge about CRC risk and screening needs, as
well as relatively passive attitudes toward initiating
screening discussions with providers, may interfere with
repeat adherence, and could be addressed through
counseling and education. Findings from this study can
inform future research and clinical practice regarding
CRC screening behavior in this understudied population. 
Supported by the American Cancer Society MRSGT-
04-204-01 (S.K. Peterson, PI).
[A20]
Can the Development of Desmoids be Predicted? 
The Use of Knowledge Discovery Techniques in Familial
Adenomatous Polyposis
Elena Manilich, James Church
Cleveland Clinic Foundation, Cleveland, Ohio
Purpose: Clinically significant desmoid tumors occur
in 12 to 15% of patients with FAP. When large or fast
growing they cause severe morbidity and even death.
Strategies to minimise their impact include delaying
prophylactic colectomy, pre-operative treatment with anti-
-desmoid drugs, and choice of some operations (e.g.
laparoscopic IRA) while avoiding others (e.g. laparoscopic
pouch). In some patients desmoid risk can be determined
by genotype or family history, but the most severe
desmoids often come as a surprise. We performed this
study to see if knowledge discovery techniques could help
predict patients who will develop desmoids.
Methods: Knowledge discovery techniques,
clustering and classification were applied to an inherited
colorectal cancer database of 557 FAP families with
8,889 family members. We analyzed pedigree
relationships, data related to clinical presentation of
FAP, test results, and follow-up. The data set was
converted to a high dimensional output appropriate for
the data mining analysis with 143 attributes for each
family member.
Results: Clustering analysis grouped family members
into two distinct clusters with a high and a low probability
of desmoids. Female patients who have a family history
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of desmoids and have been diagnosed with osteoma,
gastric polyps, and epidermoid cyst fall into the cluster
with a high probability of desmoid disease. (43 percent
in this cluster have desmoids versus 15 percent in a low
risk cluster (male patient with no family history of
desmoids, no gastric polyps, epidermoid cyst, or
osteoma). We also built a rule-based classifier that
searched for patterns in the database and represents
these in a form of association rules. Most rules
incorporate the extracolonic manifestation of Gardner’s
syndrome. For example, one of the discovered patterns
is that 88 percent of female patients with at least three
extra-colonic manifestations and duodenal polyps have
been diagnosed with a desmoid (Table 1).
Conclusion: The knowledge discovery process has
identified a series of FAP phenotypes that are associated
with a high risk of desmoid disease. Work-up of FAP
patients must include a thorough examination for extra-
colonic manifestations. Patients with these phenotypes
should be counselled and their care managed
appropriately.
[A21]
Taking a Family History can be Fun! Touch-Screen Assessment
using the Family History Score
Ellen McGannon, Susan Fay, Janet Shenal, 
Dawn Caraballo, Lisa LaGuardia, Jennifer Moench,
Michelle Ryals, Elena Manilich, James Church, 
Stacie Pallotta
David G Jagelman Registries, Department of Colorectal Surgery, Cleveland Clinic Foundation
Background: A family history of colorectal cancer
can be complex because of the multiple possible
permutations and combinations. A Family History Score
has been developed and validated to simplify familial
risk assessment. We have applied a program allowing
use of touch screen computer technology to the
calculation of familial risk of colorectal cancer using
this scoring system. In this study we report the results
of a test of the program at a women’s health fair.
Methods: The Family History Scoring System has
been published recently and its use in HNPCC families
has been described (Church JM. A scoring system for
the strength of a family history of colorectal cancer. Dis
Colon Rectum 2005; 48: 889-96. Church JM,
McGannon E, Patrick D. Validating the family history
score in Amsterdam positive families enhances its use
in the general population. Dis Colon Rectum 2005;
48: 659-60.). Patients with scores <8 are considered
at low familial risk of cancers or advanced adenomas
while scores >7 signify high risk. Scores >11 are
suggestive of a hereditary colorectal cancer syndrome.
A program was designed in which family history was
entered by answering a series of questions including
the relationships and number of affected first, second,
and combination first and second-degree relatives to
the screener, and age at diagnosis. The program
calculated the Family History Score. Each set of scores
had associated screening recommendations which were
reviewed with the participants. A table was set up at 
a women’s health fair offering a colorectal cancer risk
Table 1. (A20) 
Rule % diagnosed with desmoid
3-5 ECM and surgery: ECE and Prophylactic Colectomy 100
3-5 ECM and surgery: ECE and Dental Abnormalities 100
3-5 ECM and surgery: ECE and Fundic gland polyps 100
Female and surgery: ECE and duodenal adenomas 90
Female and 3-5 ECM and duodenal adenomas 88
ECE and fundic gland polyps and epidermoid cyst 86
3-5 ECM and surgery: ECE and congenital hypertrophy of the retinal pigment epithelium 86
ECE – extra-colonic excision; ECM – extra-colonic manifestation.
Table 1. (A21) 
Score Risk level N
0 Average population 203 (75%)
1-7 Low increased 63 (23%)
8-10 High increased 1 (0.4%)
>10 Likely HNPCC 3 (1%)
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assessment. Interested participants were asked
questions about their family history of colon cancer
and age when affected using the touch-sensitive
computer screen. No identifying information was
collected. Recommendations for surveillance were
given depending on the risk level assigned.
This study was approved by the Institutional Review
Board at the Cleveland Clinic.
Results: 270 women participated. The scores are
shown in the table. Women found the questionnaire
easy to complete and compliance was high.
The three patients with likely HNPCC had scores
of 12, 18 and 21. These families need workup by 
a genetic registry.
Conclusion: the Family History Score is a simple
way of measuring familial risk of colorectal cancer and
is suitable for use with a computer and a touch-screen.
This should improve understanding of familial risk of
colorectal cancer and compliance with screening
recommendations.
[A22]
Optimizing PCR-based assay for MSH2Δ1-6 American founder
mutation
Michelle Condie, Randall Burt, Deborah Neklason
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Collaborative Group of Americas on Inherited Colorectal Cancer, Nashville, TN 2006
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Background: An American founder genomic
deletion of exons 1-6 of the MSH2 gene in HNPCC
families has been previously characterized (Wanger et
al., 2003). As described by Wagner et al., the founder
became a Mormon in the 1800s and traveled from
Alabama to Utah. Thus, its prevalence is of particular
interest in the Utah population. The deletion is thought
to arise from a recombination event between two Alu
elements resulting in removal of 20 kb genomic DNA
including exons 1-6. A deletion-specific PCR-product
of 1.7 kb allowed for rapid identification of individuals
harboring this mutation. DNA from individuals lacking
the mutation yielded no product. Multiple labs
including ours found that this PCR reaction was not
very robust; we encountered variable results and false
negatives. Consequently, we have modified the PCR
reaction by changing the Taq DNA polymerase system,
one primer, and nesting a second primer that will yield
an additional 3 kb band from the normal MSH2 allele. 
Methods: Using a known mutation carrier as 
a positive control, three Taq DNA polymerase systems
were examined: recombinant Taq (Fermentas); FastStart
Taq (Roche) and PrimeStar HS (Takara). PCR reactions
included 0.2 μM primers, 200 μM dNTPs, 50 ng
genomic DNA, and Taq, buffers and MgCl2 as
recommended by the manufacturer. Thermocycler
conditions included a hot-start, then 30 cycles of 94°C
1 min, 57°C 15 sec, and 72°C 2 min. 
The modified PCR reaction was run as above with
the PrimeStar HS DNA polymerase (0.625u/25ul) and
1xPrimeStar buffer (1mM MgCl2) with the following
primers:
R3: 5’ GCTGAATTAGGTTTTGGAAC 3’ (5’ primer
upstream of exon 1; Wagner et al., 2003).
P2: 5’ CATAACCCTGCCTAACACAT 3’ (3’ primer
specific for wild-type product in intron 1)
F4: 5’ TGCAATTCTGAGAGTCAACA 3’ (3’ primer
for deletion product in intron 6)
Results: The PrimeStar HS DNA polymerase clearly
gave the best result. 17 individuals from a kindred with
the MSH2Δ1-6 mutation were tested using the PCR
method described. Mutation carriers yielded two bands
of 1557 bp (mutant allele) and 3141 bp (wild-type
allele), noncarriers yielded the single band of 3141
bp, and failures had no product. In addition, we
surveyed 30 probands from Utah colon cancer sibships
and no MSH2Δ1-6 mutation carriers were identified.
Conclusions: We have developed a robust PCR-
based assay for screening of the MSH2Δ1-6 American
founder mutation. This assay eliminates false negatives
through a nested PCR of the wild-type product.
Using this assay, it will be informative to ascertain
the actual prevalence of this mutation in a large set of
Amsterdam-positive individuals or individuals fulfilling
Bethesda Criteria from America.
[A23]
Probands and non-probands differ by age of onset to colorectal
cancer in Lynch syndrome
Mala Pande, Christopher I Amos, Nancy Viscofsky, 
Patrick M Lynch, Marsha L Frazier
UT M. D. Anderson Cancer Center, Houston Tx; 1155 Hermann P. Pressler, Unit 1365,
Houston Tx 77030
Key words: Lynch syndrome, screening, age of onset
Background: Lynch syndrome individuals are at an
increased lifetime risk of developing colorectal cancer
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(CRC) and certain other types of cancer because of an
inherited germline mutation in one of a set of genes
responsible for DNA mismatch repair (MMR). The median
age of cancer onset is ~45 years. However, since most
Lynch syndrome families come to light through hospital-
-identified probands, this estimate may be biased towards
a younger age of onset. Clinically, the suspicion of Lynch
syndrome arises when individuals present with CRC,
endometrial or another Lynch syndrome-related cancer
before age 50. In addition, if they have a positive family
history and meet the Amsterdam/Amsterdam II criteria
and/or if the tumor exhibits microsatellite instability or
there is loss of staining for one of the proteins expressed
by the MMR genes, mutation testing is undertaken for
Lynch syndrome. Testing of family members likely to carry
the mutation follows. The current screening guidelines
for Lynch syndrome restrict testing to those diagnosed
with CRC before 50 years of age (only recently, the
revised Bethesda guidelines 2004 have extended tumor
MSI testing up to the age of 60 years for those that do
not meet the Amsterdam criteria for family history).
Therefore, most probands have an age of onset of cancer
that reflects this early age. The family members or non-
-probands, on the other hand, are likely to have an age
distribution of cancer onset that is a closer estimate of
the true age at cancer onset in the Lynch syndrome
population because they are less subject to selection/
ascertainment bias. For example, in a recent study on 
a Finnish population, Hampel et al. (Gastroenterology,
2005) reported that the median age of CRC onset
among non-probands was much later than among
probands (61 years vs. 44 years), suggesting a need to
consider Lynch syndrome in older individuals. 
Methods: We analyzed 206 MMR mutation-carrying
individuals (93 probands and 113 non-probands) with
and without CRC, recruited at the MD Anderson
Cancer Center based on the criteria described above,
for age of onset to CRC using survival analysis. 
Results: We found that the median age of onset of
CRC was 43 years among probands but 60 years
among non-probands; this difference was statistically
significant (P≤0.001, log-rank test). Further, the earlier
age of onset among probands as compared to non-
-probands was not influenced by gender, gene involved
(hMLH1 or hMSH2) or the type of mutation (missense
vs. truncation/deletion/insertion/other).
Conclusion: Our study replicates the findings of the
Hampel study in a US population, i.e. that the median
age of CRC onset may be older in Lynch syndrome
than ~45 years as is presently assumed. This has
implications for screening guidelines for Lynch
syndrome since the current age criterion for Lynch
syndrome screening may be set too low. Our findings
suggest that many Lynch syndrome families who are
carriers of DNA mismatch repair mutation may go
undetected because they do not necessarily develop
CRC at an early age.
[A24]
The Use of Early-Onset Colorectal Carcinoma as a Marker 
for Lynch Syndrome
Joshua O Podjasek, Marc I Brand
Rush University Medical Center, Department of Colorectal Surgery; 1250 S. Indiana Ave.,
#808, Chicago, IL 60605
Key words: Lynch syndrome, colorectal cancer,
young age
Background: Approximately eighty percent of
patients with colorectal carcinoma have sporadic
disease, while twenty percent most likely have a genetic
component to their disease. Colorectal cancer is a rare
occurrence in young individuals (less than fifty years of
age) and is a major criterion for suspecting the most
common autosomal dominant syndrome predisposing
to colorectal carcinoma, hereditary nonpolyposis
colorectal carcinoma, also known as Lynch syndrome.
Methods: Detailed personal and family histories were
obtained from seventy-one patients that developed
colorectal carcinoma at an age less than fifty. These
patients were all treated at Rush University Medical
Center in Chicago, IL between 1995 and 2005. Then,
the patients were contacted by telephone, and
information was obtained regarding changes in their
personal and family histories since they were last treated.
We were particularly interested in whether there had
been a recurrence of their original diagnosis of
colorectal cancer or if a different Lynch syndrome cancer
had developed in them or in primary family members.
Results: 58 of the 71 (81.6%) reported no change in
their personal and family histories of cancer. 4 of the 
71 reported the development of a Lynch syndrome cancer,
while the remaining nine reported the development 
of cancers that are not included in Lynch syndrome. 
Conclusions: Our study suggests that early-onset
colorectal carcinoma (<50 years of age) alone should
not be used as a marker for Lynch syndrome, and that
other criteria from the Bethesda guidelines should be
met when attempting to identify families with hereditary
nonpolyposis colorectal carcinoma. The relatively low
frequency of development of Lynch syndrome in
patients with previous colorectal carcinoma at an age
less than fifty should be further confirmed with larger
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sample size, population-based studies to establish
more definitively whether early-onset colorectal
carcinoma can be used as a predictive marker for
Lynch syndrome, which may allow more effective
screening in the future. 
[A25]
Sensitivity of Statistical Models for the Prediction of Germline
Mismatch Repair Mutations
Victoria M Raymond, Wendy Kohlmann, Stephen B Gruber 
University of Michigan
Background: The identification of families at risk for
carrying a mutation in one of the mismatch repair
genes, MLH1, MSH2 or MSH6, has traditionally relied
on Bethesda guidelines, Amsterdam and Amsterdam II
Criteria, and clinical judgment. Statistical models that
estimate the probability of a deleterious mutation
provide quantitative tools to supplement guidelines and
clinical judgment. These statistical models rely on either
logistic regression (Leiden model) or a Bayesian model
incorporating Mendelian probabilities and clinical
information (MMRpro) to estimate the probability of 
a mutation. The purpose of the present study was to
estimate and compare the sensitivity of the Leiden and
MMRpro models among families with known mutations
in mismatch repair genes.
Methods: Data from 41 independent families
enrolled in the University of Michigan Cancer Genetics
Registry with known pathogenic mismatch repair
mutations were analyzed using two statistical models.
Logistic regression models incorporated age of
colorectal cancer diagnosis, fulfillment of Amsterdam
criteria, and the presence of any endometrial cancer in
the family. Bayesian models incorporated family
structure, colorectal and endometrial cancer diagnoses
and respective ages at each diagnosis. Bayesian models
were run with and without microsatellite instability data.
Information regarding the presence or absence of 
a germline mutation was assumed to be unknown 
for all families in Bayesian models. All calculations 
were performed as implemented in CancerGene at
http://www4.utsouthwestern.edu/breasthealth/cagene/.
Sensitivity was calculated at two thresholds for each
model (mutation probabilities of ≥35%, and ≥10%).
Results: Twenty-seven families (65.8%) harbored
mutations in MSH2, while 13 (31.7%) carried mutations
in MLH1, and 1 family (2.4%) had a mutation in MSH6.
At a threshold of 35% mutation probability, the sensitivity
of MMRpro was 68.3%, compared to 41.5% for the
Leiden model. At a threshold of 10% mutation probability,
the sensitivity of MMRpro was 75.6%, compared to
73.2% for the Leiden model. Adding information about
microsatellite instability increased the sensitivity of
MMRpro at both thresholds (sensitivity = 70.7% and
82.9% at thresholds of 35% and 10%, respectively), and
did not change the sensitivity of the Leiden model.
Conclusions: Bayesian modeling using MMRpro
outperforms logistic regression modeling as implemented
in the Leiden model. The sensitivity of MMRpro is
especially high when incorporating information from
microsatellite instability testing (83%), but still misses some
families with identifiable mutations. MMRpro is a valuable
aid in the identification of individuals at risk of carrying
a mismatch repair mutation but is not a substitute for
clinical judgment. 
[A26]
Starting a New Registry: Critical Design Components
Angela Schwab, Lisa Bredthauer, Randall Burt
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 
Key words: registry, development, coordination 
Background: There are many aspects to consider
when starting a new research-based registry. Since its
inception in 1998, coordinators of the Familial Colon
Cancer Registry (FCCR) have been approached on
several instances to discuss the Registry’s objectives,
operations, and challenges. This project involves
documenting the design elements and components
needed to build a successful registry.
Methods: By networking with other registries, a list of
common registry objectives was compiled. These include
an educational component, data and biospecimen
collection, research collaboration, development, and
maintenance. Each objective comprises several key
elements coordinators should consider when constructing
a registry. 
Results: When first developing a registry, it is necessary
to define the goals, establish eligibility requirements,
identify funding sources, obtain institutional support,
create a research study review process, and determine if
it will be research or clinically focused. Once these have
been identified, the data and biospecimen collection
options can be more clearly defined. Frequently collected
items include medical records, family history information,
genetic test results, blood, and tissue samples. When
data is collected, it is imperative that the information be
easily extracted from the database. The ultimate goal of
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a research-based registry, like the FCCR, is to facilitate
translational research. In order to create mutually
beneficial research collaborations, each study requesting
information should pass the registry’s approval process. 
Once a registry has been established, many day-to-
-day operations must be addressed such as marketing,
staffing, and working with the Institutional Review Board.
Furthermore, if an institution is able to support educational
components in their registry, various options may be
considered including workshops, outreach presentations,
newsletters, fact sheets, and having staff available to
answer medical questions. 
Conclusions: When starting a new research
resource, it is often helpful to consult with coordinators
of established registries. There are many types of
registries; most have educational, clinical, and research
objectives. If a registry is to function successfully and
meet its objectives, careful consideration must be given
to each of these components and how they interact.
Registry personnel must also contribute an immense
amount of foresight and organization to build 
a valuable resource for investigators while maintaining
a positive working relationship with participants.
[A27]
Reduced mRNA stability contributes to decreased expression 
of the growth suppressor gene cyclin dependent 
kinase-2-associated protein-1 (CDK2-AP1) 
in microsatellite unstable (MSI) colorectal cancer (CRC) 
Joongho Shin, Ziqiang Yuan, Prashanth Sreeramoju, 
Tara Kent, Kenneth Fordyce, John Kim, Victor Wang,
Thomas K Weber
Departments of Surgery and Molecular Genetics, Albert Einstein College of Medicine, 
1300 Morris Park Avenue, Ullmann 707, New York, NY 10461
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CDK2-AP1
Introduction: In our most recent presentation to this
forum (Salt Lake City, 2006) we demonstrated that
decreased cyclin dependent kinase-2-associated protein
(CDK2-AP1) expression in MSI CRC is associated with 
a del T mutation in the poly T (8) repeat of the 3’
untranslated region (UTR) of the gene. Our present study
tests multiple hypotheses: H-1; The observed del T
mutation in the 3’ UTR of the CDK2-AP1 gene is
functionally significant. H-2; Decreased CDK2-AP1
expression observed in MSI CRC and associated with the
del T mutation results from reduced CDK2-AP1 mRNA
stability. H-3; The del T mutation is somatic in nature. 
Methods: To test the functional significance of the del
T mutation (H-1) we employed a mutagenesis functional
assay using a Lentiviral Vector transfer system 
(LV-pRRl.sin.PPT.hPGK.EGFP) to introduce both mutant
and wild type poly (T) 8 3’ UTR sequences into separate
human CRC SW48 cell lines. Green florescent protein
(GFP) expression measured transduction efficiency and
surrogate CDK2-AP1 expression. CDK2-AP1 mRNA
stability (H-2) was measured using a standard
actinomycin D assay and the mRNA structure folding
software mfold 3.2. Four human MSI CRC tumor/
adjacent normal tissue pairs were sequenced for
evidence of the del T mutation (H-3). 
Results: H-1; Mutant (del T) samples demonstrated
significantly reduced GFP expression compared to wild
type GFP-3’-UTR as measured by both FACS and real-
-time PCR. H-2; Both the actinomycin D assay and
mfold software demonstrated significantly reduced
mRNA stability for the del T product compared to the
wild type. H-3; Automated sequencing demonstrated
the del T poly (T) 8 mutation in 4/4 human MSI CRCs.
Del T was not observed in the 4 adjacent to tumor
“normal” samples. 
Conclusions: These results strongly support our
hypotheses that the del T mutation in the poly (T) 8 repeat
sequence in the 3’ UTR of CDK2-AP1 is functionally
significant (H-1), resulting in decreased CDK2-AP1
expression secondary to decreased mRNA stability (H-2).
Importantly, the CDK2-AP1 del T mutation observed in
human MSI CRC appears to be a somatic, non-germline
genetic event (H-3). We conclude that these novel results
significantly advance our understanding of the role of
CDK2-AP1 in human MSI CRC.
Funding: for this project was provided by an
American Cancer Society Research Scholar award to
TKW, a Cancer Research Foundation of America
award to ZY and a Colon Cancer ChallengeR Research
Scholar award to ZY.
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A Lynch Syndrome Medical History Project
Cynthia Soto-Azghani, Ali Azghani
Abstract submitted to Larry Rusin, MD, CGA-ICC Vice President at Lawrence.c.rusin@lahey.org
Key words: Lynch syndrome, HNPCC, MSH2
Background: A Texas family continues to exist in spite
of a 50-year struggle with Lynch syndrome, an inherited
condition also known as hereditary nonpolyposis colon
cancer, or HNPCC. Types of cancer diagnosed within
Hereditary Cancer in Clinical Practice 2007; 5(1)50
this family include colon, uterine, thyroid, breast, kidney,
melanoma, pancreas, liver, and brain. We sought to
consolidate a collection of verbal and written medical
history into a concise chronological timeline document
to include the years 1949-2006. The psychosocial
impact of the disease on this family was also observed
and noted. 
Methods: We will continue follow-up communications
with the affected family members to update data
concerning diagnosis, treatments, and outcome. The
data will be presented in a timeline format coinciding
with the family pedigree. Psychosocial issues discussed
within family circles will be described. Finally, various
methods to promote family awareness and available
clinical studies will also be explored. The names of the
Texas family members will remain anonymous.
Results: We found numerous cases of uterine,
colon, liver, and a case of kidney and thyroid cancer
among members of this family. Results of genetic testing
in several members of the family revealed a mutation
for Lynch syndrome (MSH2). In addition, tissue samples
tested so far showed microsatellite instability.
Conclusions: Aside from a valuable family history,
we hoped the data would be a resource for clinicians
and scientists in addressing new hypothesis for basic
and clinical investigations and educational materials.
In addition, the recent scientific data documented in
this project may stimulate collaborations among Lynch
syndrome families and the clinical teams to develop
ideas for future studies. 
Recognizing the hereditary aspect of this disease and
the family’s efforts on prevention and early detection of
Lynch syndrome cancers may enhance long-term survival
and alleviate the devastating impact on the affected
families. 
[A29]
MLH1 germline epimutations in selected patients 
with early-onset nonpolyposis colorectal cancer
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1Familial Cancer Unit, Human Cancer Genetics Program, Spanish National Cancer Center
(CNIO), Melchor Fernandez Alamgro 3, 28029 Madrid, Spain; 2Human Genetics Group,
Human Cancer Genetics Program; 3Tumor Bank Unit, Molecular Pathology Program,
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Background: Hereditary nonpolyposis colorectal
cancer (HNPCC) is caused by germline mutations in
components of the mismatch repair (MMR) system,
mainly in MLH1 and MSH2 genes, and to a lesser
extent in MSH6 and PMS2. Hypermethylation of CpG
islands of the promoter sequence has been shown to
be an important mechanism of gene silencing, and in
particular of tumor suppressor genes in sporadic
cancer. In the particular case of the MLH1 gene,
promoter hypermethylation in colorectal tumors
correlates well with loss of the MLH1 protein in
sporadic MSI cases. Recently, germline epigenetic
inactivation of MLH1 has been reported in a number
of patients with early-onset colorectal cancer among
other characteristics.
Patients and methods: From a total of 109
microsatellite instability-positive HNPCC-suspected
families, eleven showed lack of MLH1 tumor expression
and no germline mutations in the MMR genes. In nine
of these cases and in three additional patients with
multiple tumors, the study of germline MLH1 promoter
hypermethylation was performed by means of MSP and
COBRA. For positive cases, results were confirmed in
saliva DNA and MLH1 LOH was analyzed in tumor
DNA. MLH1 expression was analyzed in 24 additional
colorectal tumors belonging to patients with multiple
primary tumors. 
Results: One of the selected patients resulted
positive for the MLH1 epimutation. He had developed
an epidermoid lip carcinoma and a colorectal tumor
with microsatellite instability, no MLH1 expression and
LOH of the gene. Parents and siblings did not carry
the epigenetic alteration. None of the tumors
belonging to the patients with several malignancies
showed any lack of MLH1 expression.
Conclusions: We consider that screening for MLH1
germline epimutations should be performed in early-
-onset colorectal cancer patients with MSI, lack of
MLH1 expression, and no germline mutations. In
several cases the presence of several primary tumors
has been observed and data suggest that this
epigenetic alteration is not inheritable. In addition, the
possibility of preventive treatment with demethylating
agents for these patients seems very promising, taking
into account the reversibility of epigenetic changes.
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